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To provide the information that is necessary for making the proper use of kampo medicines, we have proposed the adequate
methodology focused on the following issues: (i) kampo medicines emphasize the eﬀects produced by the combination of herbal
drugs rather than the individual eﬀect of any single herb and (ii) Intestinal CYP3A has become a key factor for the bioavailability
oforallyadministrated drugs. In the present study, we investigated both the in vivo andin vitro eﬀects of Saireito and Hochuekkito
(kampo formulas) on CYP3A activities. From our study, oral pre-treatment with Saireito or Hochuekkito did not aﬀect the
pharmacokinetics of nifedipine after intravenous administration to rats.When nifedipine was administered to rat intrajejunum, a
signiﬁcant decrease of AUC was showed by pre-treatment with both kampo formulas. Saireito pre-treatment led to 80% decrease
in Cmax of nifedipine. Saireito caused signiﬁcantincreases in both protein expression and metabolic activity of CYP3A in intestinal
microsome, whereas it had no eﬀect on CYP3A in hepatic microsome. Our result also showed that this aﬀect of Saireito can be
gone by wash-out with 1 week. These ﬁndings demonstrated that Saireito may induce CYP3A activity of intestine but not of liver
in rats. When resources for research are limited, well-designed scientiﬁc studies except clinical trials also have many advantages.
1.Introduction
The aims for concomitant use of kampo formulas with
prescription medicines are: (i) enhancement of medical
eﬀects;(ii) reductionsofsideeﬀects;and (iii)minimizing the
dosage of drugs administered [1]. In Japan, kampo medicine
was oﬃcially integrated into the Japanese healthcare system.
Many Japanese medical doctors utilized kampo formulas in
their daily practice either as the sole source of therapy or
in combination with prescription medicines [2]. Coinciden-
tally, this reversal has occurred following highly publicized
problems with herbal medicine safety, reliability and eﬃ-
cacy. Signiﬁcant harm has been demonstrated by negative
interactions of cytochrome P450 (CYP) 3A substrates with
the popular herbal medicine, St John’s Wort (Hypericum
perforatum L.) [3, 4].
Kampo medicine is a multi-component system since
it is composed of more than one herbal medicine; it is
diﬃcult to predict the interaction by accumulating the eﬀect
of each component herbal plant. With the development
in elucidating the pharmacology of kampo medicines, it is
found that each herbal plant plays its indispensable role in
a kampo medicine [2]. Saireito and Hochuekkito are major
kampo formulas (Table 1) in Japan and they show clinical
eﬃcacy in combination with prescription medicines, that
is, reducing the dose or side eﬀe c to fs t e r o i d so ra n t i c a n c e r
drugs [5] .H o w e v e r ,b e c a u s eo ft h ea b s e n c eo fd a t at o
guide concomitant use of kampo formulas with prescription
m e d i c i n e si ti sd i ﬃcult to ensure its robustness.
The safety proﬁles of multi-medication increasingly
require documentation of CYP450 and P-glycoprotein inter-
action [6]. To provide the information that is necessary for2 Evidence-Based Complementary and Alternative Medicine
Table 1: List of components in Saireito and Hochuekkito.
Crude drugs Ratio crude-drugs component
Latin name (Japanese
name) Botanical origin Medicinal part
Saireito Hochuekkito
Amount/day
(g) (%,w/w) Amount/day
(g) (%,w/w)
Bupleuri Radix (Saiko) B u p l e u r u mf a l c a t u mL .
(Umbelliferae) Root 7.0 17.5 2.0 8.3
Pinelliae Tuber (Hange) Pinellia ternata Breitenbach
(Araceae) Tuber 5.0 12.5 — —
Scutellarine Radix (Ogon) Scutellaria baicalensis Georgi
(Labiatae) Root 3.0 7.5 — —
Ginseng Radix (Ningin) Panax ginseng C.A. Meyer,
(Araliaceae) Root 3.0 7.5 4.0 16.7
Glycyrrhizae Radix (Kanzo)Glycyrrhiza uralensis Fisher,
(Leguminosae) Root 2.0 5.0 1.5 6.3
Zingiberis Rhizoma
(Shokyo)
Zingiber oﬃcinale Roscoe
(Zingiberaceae) Rhizome 1.0 2.5 0.5 2.1
Zizyphi Fructus (Taiso) Zizyphus jujuba Miller var.
inermis Rehder (Rhamnaceae) Fruit 3.0 7.5 2.0 8.3
Astragali Radix (Ogi)
Astragalus membranaceus
Bunge, A.mongholicus B.
(Leguminosae)
Root — — 4.0 16.7
Atractylodis Lanceae
Rhizoma (Sojutsu)
Atractylodes lancea De
Candolle, A.chinensis
Koidzumi (Compositae)
Rhizome 3.0 7.5 4.0 16.7
Angelicae Radix (Toki)
Angelica acutiloba Kitagawa,
A. a. K. var. sugiyamae Hikino
(Umbelliferae)
Root — — 3.0 12.5
Auranntii Nobilis
Pericarpium (Chimpu)
Citrus unshiu Markovich,
(Rutaceae) Peel — — 2.0 8.3
Cimicifugae Rhizoma
(Shoma)
Cimicifuga foetida L.
(Ranunculaceae) Rhizome — — 1.0 4.2
Alismatis Rhizome
(Takusha)
Alisma orientale Juzepczuk
(Alismataceae) Rhizome 5.0 12.5 — —
Polyporus (Chorei) Polyporus umbellatus Fries
(Polyporaceae) Sclerotium 3.0 7.5 — —
Cinnamomi Cortex (Keihi) Cinnamomum cassia Blume
(Lauraceae) Bark 2.0 5.0 — —
Poria (Bukuryo) Poria cocos Wolf (Polyporaceae) Sclerotium 3.0 7.5 — —
Total: 40.0g Total: 24.0g
Kampo products, Saireito and Hochuekkito, were provided according to JPXV (http://jpdp.nihs.go.jp/jp15e).
health policy and oﬃcial recommendations, we have focused
on the following issues: (i) kampo formulas emphasize the
eﬀects produced by the combination of herbal drugs rather
than the individual eﬀect of any single herb; (ii) intestinal
CYP3A has become a key factor for the bioavailability of
orally administrated drugs. Especially, nifedipine is one of
the drugs that have been suggested to undergo signiﬁcant
ﬁrst-pass metabolism by CYP3A in the intestine [7]. Thus,
we tried to evaluate the synthetic eﬀect of kampo as a
multi-herb formula and to obtain useful information for
providing warning and proper advice to patients in clinical
practice.
2.Materialsand Methods
2.1. Materials. Saireito and Hochuekkito extract granules
(Table 1)[ 8] were purchased from Tsumura & Co., Ltd
(Tokyo, Japan) (Serial number: 25026892 for Saireito and
23029192 for Hochuekkito). Polyethylene glycol (PEG) 400
was purchased from Nacalai Tesque (Kyoto, Japan). Nifedip-
ine was obtained from Sigma Chemical Co. (St Louis, MO,
USA). Oxidized nifedipine was purchased from Sumitomo
Chemical Co., Ltd. (Osaka, Japan). Trypsin inhibitor (from
soybean) and (p-amidinophenyl) methanesulfonyl ﬂuoride
hydrochloride (APMSF) were obtained from Wako Pure
Chemicals Ltd. (Osaka, Japan). NADP, glucose-6-phosphateEvidence-Based Complementary and Alternative Medicine 3
and glucose-6-phosphate-dehydrogenase were purchased
from Oriental Yeast Co., Ltd. (Tokyo, Japan). All other
chemicals available were of the ﬁnest reagent grade.
2.2. Animals. Male Wistar/ST rats (Japan SLC, Hamamatsu,
Japan), weighing 220–290g, were used in accordance with
the Guidelines for Animal Experimentation of Mukogawa
Women’s University, which are based on the Guidelines for
Animal Experimentation of the Japanese Association for
Laboratory Animal Science.
2.3. Three-Dimensional HPLC Analysis. Granules of Saireito
and Hochuekkito (1.0g) were extracted with methanol
(20mL) under ultrasonication for 30min, and were cen-
trifuged at 1500g for 5min. The supernatant was ﬁltrated
with a membrane ﬁlter (0.45µm) and then submitted for
HPLC analysis (30µL). HPLC apparatus consisted of a
Shimadzu LC 10A (analysis system software: CLASS-M10A
ver. 1.64,Tokyo, Japan) equippedwith a multiplewavelength
detector (UV 200–400nm) (Shimadzu SPD-M10AVP, diode
array detector) and an auto injector (Shimadzu CTO-10AC).
HPLC conditions were described as follows: column, ODS
(TSK-GEL 80TS, 250 × 4.6mm i.d., TOSOH, Tokyo, Japan);
eluant, (A) 0.05M AcONH4 (pH 3.6) (B) 100% CH3CN. A
linear gradient of 90% A and 10% B changing over 60min to
0% A and 100% B was used (and 100% B was continued for
20min); temperature, 40◦C; ﬂow rate, 1.0mLmin−1.F i g u r e s
1(a) and 1(b) show the chemical proﬁles of Saireito and
Hochuekkito, respectively.
2.4.Pre-Treatment of Kampo Medicines. The extract granules
of Saireito and Hochuekkito were suspended in solvent of
PEG 400/water (1:1) as a concentration of 0.3gmL−1 and
0.25gmL−1, respectively, and agitated overnight. Then, rats
were orally administered with these suspensions for 7 days
(1.5gkg−1 in Saireito and 1.25gkg−1 in Hochuekkito). The
control group was administered with solvent.
2.5. In Vivo Pharmacokinetic Experiment. Intravenous or
intrajejunum administration of nifedipine was performed
by the method as described earlier [9]. Brieﬂy, following
the pre-treatment of kampo medicine, rats were allowed
to fast before the experiments for 18–20h with water
freely available. After rats had been anesthetized with
ethyl carbamate (1gkg−1), nifedipine dissolved in PEG
400/water(1:1)wasadministered intravenouslyorintrajeju-
nally (3 mgmL−1 kg−1). After administration, blood samples
(0.5mL) from the jugular vein were collected periodically.
The samples were centrifuged, and the plasma fraction was
frozen at –20
◦C until the HPLC assay of nifedipine.
2.6. Nifedipine Measurement of In Vivo Experiment. The
nifedipine concentrations in rat plasma were measured by
HPLC method reported by Takahashi et al. [10]. The plasma
samples(200µL)weredeproteinizedwith acetonitrile(1mL)
and centrifuged. Supernatants (1mL) were collected and
evaporated before being dissolved with mobile phase and
80µL was injected into the HPLC. The HPLC system
consisted of a pump (LC-10ADvp, Shimadzu, Kyoto, Japan),
and a UV detector (SPD-10Avp, Shimadzu, Kyoto, Japan)
andanintegrator(SCL-10Avp,Shimadzu,Kyoto,Japan).The
column was TSKgel ODS-80TM column (4.6 × 150mm:
TOSOH Corp., Tokyo, Japan) with the mobile phase of
10mM KH2PO4 buﬀer/acetonitrile (55 : 45) at a ﬂow
velocity of 1mL/min at 40
◦C. Nifedipine was detected as the
absorbance at 350nm. Nifedipine concentrations for each of
the samples were calculated by a standard calibration curve
for nifedipine (0.3–150.0µgmL −1). Correlation coeﬃcients
were obtained >0.998.
2.7. Pharmacokinetic Analysis. The peak plasma concentra-
tion (Cmax)a n dt h et i m et or e a c hCmax (Tmax) of nifedipine
were determined from the actual data obtained after oral
administration. The plasma concentration-time data of
intravenous or intrajejunum administration was assessed
by non-compartment analysis using MOMENT [11]b a s e d
on the moment analytic method [12]. Half-life (t1/2)w a s
calculated by this computer program using the last four
point of the concentration. The area under the plasma
concentration–time curve from zero to inﬁnity (AUC0−∞)
and the mean residence time (MRT) from zero to inﬁnity
was also calculated by the same computer program. The
absolute bioavailability (F) of nifedipine after intrajejunum
administration (i.j.) was estimated as follows: (AUCi.j. ×
Di.v.)/(AUCi.v. × Di.j.) × 100.
2.8. Preparation of Liver and Intestine Microsomes. The livers
of rats were removed,minced, rinsed in ice-cold 0.1M
potassium phosphate buﬀer (pH 7.5), then homogenized
in a Teﬂon-glass homogenizer immersed in ice using 4mL
o ft h es a m eb u ﬀer per gram of liver. The homogenate was
centrifuged at 9000g for 10min at 4◦C, the pellet was
discarded, and the supernatant was centrifuged at 100000g
for 60min at 4◦C. The resultant supernatant was discarded
and the pellet (microsomal fraction) was resuspended in
0.1M potassium phosphate buﬀe ra n ds t o r e da t– 8 0
◦Cu n t i l
use. The small intestines of rats were removed and ﬂushed
with ice-cold 0.1M potassium phosphate buﬀer (pH 7.5)
containing 0.1mM EDTA, 0.5mM dithiothreitol and 2mM
APMSF. An incision allowed removing the villous layer by
scraping with a glass slide. The mucosa was suspended in the
same buﬀer containing 0.5mgmL−1 trypsin inhibitor, and
homogenized in a Teﬂon-glass homogenizer and centrifuged
at 10000g for 20min at 4◦C. Then the microsomal fraction
was obtained by centrifuging the supernatant at 100000g
for 60min at 4◦C, and the pellets were resuspended in 0.1M
potassium phosphate buﬀer at –80
◦C until use. The protein
concentrations of these microsomes were determined by the
method of Lowry et al. [13] using bovine serum albumin as
the standard.
2.9.InVitroNifedipine MetabolicStudybyMicrosomes. Inthe
microsome experiment, the incubation time was determined
to be 10min since the time-oxidized nifedipine formation
rate curve has linear relationship at this time. The amount of
oxidized nifedipine was detected and the formation rate was4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Chemical proﬁle of Saireito (a) and Hochuekkito (b) analyzed by three-dimensional HPLC.Evidence-Based Complementary and Alternative Medicine 5
calculatedwhen nifedipine concentration was in the range of
0–200 µM. Km and Vmax values were calculated according to
the Lineweaver-Burk plots.
The incubation mixture (ﬁnal volume 0.5mL) con-
tained liver or intestine microsomes suspension (0.5mg
protein), 5mM MgCl2, 100mM sodium phosphate buﬀer
pH 7.4 and nifedipine solution. Nifedipine was dissolved in
methanol (nifedipine ﬁnal concentration: 20µM; methanol
ﬁnal concentration: not >1%, v/v). After pre-incubation of
mixture with shaking for 5min at 37◦C, the enzyme reaction
was initiated by addition of NADPH generating system
consisting of 2mM NADP+, 10mM gluconse-6-phosphate,
1U glucose-6-phosphate dehydrogenase. After 10min of
incubation, the reaction was terminated by addition of
2.5mL acetonitrile. The mixture was centrifuged at 10000g
for 15min at 4◦C, and 1mL of supernatant was taken for
HPLC measurement of oxidized nifedipine, a metabolite of
nifedipine.
2.10. Oxidized Nifedipine Measurement of In Vitra Exper-
iment. Supernatants (1mL) were evaporated before being
dissolved with mobile phase (200µL), and 90µLw a si n j e c t e d
into the HPLC. The HPLC system was described earlier. The
column was TSKgel ODS-80TM column (4.6 × 150mm:
TOSOH Corp., Tokyo, Japan) with the mobile phase of
water/acetonitrile (57:43) at a ﬂow velocity of 1mLmin−1
at 40
◦C. Oxidized nifedipine was detected as the absorbance
at 254nm. Oxidized nifedipine concentrations for each of
the samples were calculated by a standard calibration curve
for oxidized nifedipine (1.0–200.0µgmL −1). Correlation
coeﬃcients were obtained greater than 0.998.
2.11. In Vivo Reversibility Experiment. The pre-treatment of
Saireito to the rats was described above. After this treatment,
following the cessation of Saireito for 1 week, the in vivo
pharmacokinetic experiment was examined.
2.12. Measurement of CYP3A Protein on Rat Intestine or
Liver. The liver and small intestine of rat were homogenized
in a Teﬂon-glass homogenizer immersed in ice using lysis
buﬀercontaining 150mM NaCl,10mM Tris(pH7.4),1mM
EDTA, 1% Triton X-100, 1% deoxycholic acid and protease
inhibitor mixture, followed by centrifugation at 1500g for
10min. Protein concentration was determined by the BCA
proteinassayreagentkit(Pierce,Rockford,USA),andbovine
serum albumin was used as a standard. Proteins (12µg)
from total cell lysate were analyzed by SDS-PAGE (10%
gel). After blotting, the Immobilon-P membrane (Millipore
Corp., Billerica, USA) was blocked with 5% skim milk in
PBS with 0.5% Tween 20 at room temperature for 1h.
Immunoblots were incubated at room temperature for 1h
with the primary monoclonal antibody to CYP3A (1:1000;
DaiichiPure ChemicalsCo., Ltd,Tokyo,Japan). After further
washing, the membranes were incubated for 1h with anti-
rabbit IgG horseradish peroxidase conjugate (1:3000). The
protein was visualized by exposing the membrane to Kodak
ﬁlm for 1–5min in a dark room. Blots were reprobed
with antibody to GAPDH as a loading control. Quantitative
Table 2: Eﬀects of oral pre-treatment with Hochuekkito or Saireito
on the pharmacokinetic parameters of nifedipine after i.v. or i.j.
administration to rats.
Parameter Control Hochuekkito Saireito
i.v.
AUC0−∞ (µgmL −1 745 ± 129 807 ± 76 840 ± 91
min−1)
t1/2 (min) 37.4 ± 3.6 41.4 ± 4.9 35.0 ± 6.7
MRT 37.3 ± 3.6 47.2 ± 8.0 41.4 ± 7.2
i.j.
Cmax (µgmL −1) 5.88 ± 0.61 4.12 ± 0.52∗ 3.40 ± 0.52∗
Tmax (min) 22.5 ± 8.66 30.0 ± 21.2 15 ± 0
AUC0−∞ (µgmL −1 421 ± 56 285 ± 55∗ 215 ± 54∗
min−1)
t1/2 (min) 37.1 ± 5.4 41.9 ± 5.3 41.8 ± 2.5
MRT (min) 58.4 ± 8.3 60.0 ± 4.8 54.8 ± 5.1
F (%) 56.6 ± 7.6 35.3 ± 6.8∗ 25.6 ± 6.4∗
Each value represents the mean ± SD of 4 or 5 rats.
The nifedipine solution (3mg/kg) was intravenously (i.v.) or intrajejunal
(i.j.) administrated to rats after 7 days pre-treatment with Hochuekkito or
Saireito. ∗P <. 05 compared with control.
analysisofimmunoblottedbandwasperformedbycomputer
program (Scion Image, version Beta 4.0.3).
2.13. Statistical Analysis. All results were expressed as mean
± SD. The statistical analysis was conducted using Student’s
or Welch’s t-test for the diﬀerences between two groups, and
using one-way ANOVA followed by Bonferroni’s multiple
analysis for the diﬀerences among multiple groups by the
computer software “Statcel 2” [14]. A diﬀerence of P < .05
was considered statistically signiﬁcant.
3.Results
3.1. Pharmacokinetic Comparison of Nifedipine Administered
Intraveneously or Intrajejunally In Vivo Study. The eﬀects
of repeated administration of kampo formulas on the
pharmacokinetics of nifedipine, which is a substrate for
CYP3A, were examined in vivo and following in vitro.
When nifedipine was intravenously administered (i.v.) to
rats pre-treated with Saireito (1.5gkg−1) or Hochuekkito
(1.25gkg−1) for 1 week, their plasma concentration–time
proﬁle and pharmacokinetic parameters were unaﬀected as
compared with the control group (Figure 2(a) and Table 2).
Whereas, when nifedipine was intrajejunally administrated,
Saireito pre-treatment led to a shorter Tmax compared with
that of control group, and the Cmax was decreased to
∼79%. Thus, AUC0−∞ became ∼43% of that of the control
group (Figure 2(b) and Table 2). When rat was treated with
Hochuekkito, the AUC0−∞ was ∼71% of that of control
groupalthoughnodiﬀerencewasobservedinCmax and Tmax.
In addition, the value of F was 56.6% in the control group;
however, after treatment with Saireito or Hochuekkito, the
values of F were 25.6 and 35.3%, respectively.6 Evidence-Based Complementary and Alternative Medicine
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Figure 2: (a) Eﬀects of oral pre-treatment with Saireito and Hochuekkito on the plasma concentration of nifedipine after intravenous
administration to rats. (b) Eﬀects of oral pre-treatment with Saireito and Hochuekkito on the plasma concentration of nifedipine after
intrajejunum administrationto rats.Symbols:control treated with theonlysolvent(open circle); pre-treatment with Saireito(ﬁlled triangle)
and Hochuekkito (ﬁlled circle) for 1 week, respectively. Each point and vertical bars represent the mean ± SD (n = 4).
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Figure 3: (a) Nifedipine oxidation rates and Lineweaver-Burk plots in rat intestinal microsomes. (b) Nifedipine oxidation rates and
Lineweaver–Burk plots in rat hepatic microsomes.Symbols:control treated with the solvent (open circle); pre-treatment with Saireito (ﬁlled
triangle) and Hochuekkito (ﬁlled circle) for 1 week, respectively. Each point and vertical bars represent the mean ± SD (n = 4–6).
3.2. The Metabolic Activity of Nifedipine for In Vitro Study.
To investigate the eﬀect of kampo formulas on nifedipine
metabolism, we prepared the microsomes of liver and small
intestine from rat given Saireito or Hochuekkito orally in
advance for 1 week as in vivo experiment. Then, microsome
was prepared, respectively, to study the aﬀect of kampo
medicines on microsome CYP3A.
The concentration proﬁles were described by Line-
weaver-Burk plots and enzyme kinetic parameters were
summarized in Table 3. In the liver microsome prepared
from repeated pre-treatment of kampo formulas (Saireito
and Hochuekkito),theKm valuesand Vmax valuesamong the
three groups were similar (Figure 3(a) and Table 3). When
small intestine microsome was used, the metabolism of
nifedipine was increased (Figure 3(b)). The Vmax values for
control group was 0.255 ± 0.020pmolmin−1 mg−1 protein,
and the values for the Saireito and Hochuekkito treated
groups were 0.432 ± 0.029pmolmin−1 mg−1 protein and
0.341 ± 0.048pmolmin−1 mg−1 protein, respectively. The
Km values of three groups were not signiﬁcant as shown
in 66.3 ± 6.8µmolL−1 of control, 68.7 ± 8.0µmolL−1 of
Saireito and 61.0 ± 5.3µmolL−1 of Hochuekkito. SigniﬁcantEvidence-Based Complementary and Alternative Medicine 7
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Figure 4: (a) Eﬀects of Saireito and Hochuekkito on CYP3A protein expression levels in rat small intestine. (b) Eﬀects of Saireito on CYP3A
protein expression levels in rat smallintestine and liver. The band intensities were normalized with that of GAPDH. Results are means ± SD
from triplicate experiments. ∗P < .01 compared with control.
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Figure 5: The alteration of nifedipine plasma consentration of
intrajejunum administration after Saireito wash-out experiment.
increases in the Vmax values for kampo medicines treated
groupswerefound,andthisresultconﬁrmedtheacceleration
of CYP3A activity in small intestine.
Table 3: Eﬀects of oral pre-treatment with Hochuekkito or Saireito
on kinetic parameters of nifedipine oxidation by rat intestinal or
hepatic microsomes.
Km (µmolL−1) Vmax (nmolmin−1
mg−1 protein)
Intestine
Control 66.3 ± 6.8 0.255 ± 0.020
Hochuekkito 61.0 ± 5.3 0.341 ± 0.048∗
Saireito 68.7 ± 8.0 0.432 ± 0.029∗
Liver
Control 66.4 ± 7.5 4.50 ± 0.81
Hochuekkito 58.4 ± 2.2 5.12 ± 0.88
Saireito 60.5 ± 8.4 5.05 ± 0.48
Each value represents the mean ± SD of 4 or 5 experiments. The kinetic
parameters were calculated from the Linewaver-Burk plots in Figure 3 or
Figure 4.
∗P <. 05 compared with control.
3.3. The Inﬂuence of Kampo Formulas on CYP3A Protein
Expression in Liver and Small Intestine. Our in vivo results
showed that the treatment of Saireito or Hochuekkito
would aﬀect the metabolism of nifedipine, and the in vitro
results indicated an increase in CYP3A activity in the small
intestine but not in liver. Western blot was performed
to compare the liver and small intestine CYP3A protein
expression level in control group to those in the Saireito and
Hochuekkito treated groups (Figure 4). In small intestine,8 Evidence-Based Complementary and Alternative Medicine
Saireito and Hochuekkito treatment increased the CYP3A
expression levelsby2.6-and1.7-fold[Figure 4(a)).Asshown
in Figure 4(b), after Saireito treatment, although CYP3A
expression level in small intestine was signiﬁcantly induced,
no eﬀect was observed on the CYP3A expression level in
liver.
3.4. The Eﬀect of Saireito Wash-out on the Pharmacokinetics
of Nifedipine. The signiﬁcant eﬀect of Saireito on nifedipine
plasma concentration had been conﬁrmed by both in vivo
and in vitro experiments. Next, after administrated with
Saireito for 1 week, rats were further raised for another
1 week without administration of any medicines. The
plasma concentration–time proﬁle of nifedipine adminis-
trated intrajejunally was measured (Figure 5). After wash-
out, similar proﬁles were resulted between the groups with
or without Saireito. The Cmax,– Tmax,– A U Cv a l u e si nt h e
control group were 6.74 ± 1.44µgmL −1, 18.8 ± 7.5min,
486 ± 145µgmL −1 min−1 and these valuesin Saireito treated
group were 6.52 ± 1.76µgmL −1, 22.5 ± 8.7min, 545 ±
136µg−1mL−1 min−1, respectively. The eﬀects of Saireito on
thepharmacokineticparametersofnifedipinewerenolonger
observed 1 week after the withdrawal of Saireito.
4.Discussion
In the present study, we investigated both the in vivo and
in vitro eﬀects of Saireito and Hochuekkito on CYP3A
activities. The most important ﬁndings of this study are the
observed interaction for kampo formulas between intestinal
CYP3A and a decrease in F of nifedipine. We found
that the pharmacokinetic parameters of nifedipine after
intrajejunum administration were signiﬁcantly decreased by
the continuous ingestion of Saireito and Hochuekkito in
advance for 1 week, while the disposition of nifedipine after
intravenous administration was not altered. Repeated treat-
ment with kampo formulas increases the rate of metabolism
of nifedipine, indicating an increase in CYP3A activity in
the intestine. Saireito and Hochuekkito caused signiﬁcant
increases in the metabolic activity of CYP3A in intestinal
microsome, whereas it had no eﬀect on CYP3A in hepatic
microsome.
Early identiﬁcation of drugs that interact with kampo
medicines and the mechanism involved is important. The
ﬁrst-pass metabolism of nifedipine was reported to be larger
in the small intestine than that in liver [7]. Nifedipine has
beensuggestedtobeanidealprobeforascertaining intestinal
CYP3A activities. Due to increased intestinal CYP3A, several
mechanisms for adecrease in thebioavailabilityof nifedipine
are conceivable. Although the eﬀects of herbal medicines on
thefunctionofP-glycoprotein(MDR)mayalsobeimportant
when considering the mechanism of the changes in the
pharmacokinetics of orally administered drugs during the
absorption process [3], it can be excluded in this case,
since nifedipine has been reported not to be a substrate for
MDR [15, 16]. Taking into account that the disposition of
nifedipine after intravenous administration was not altered
by the treatment with kampo formulas, it is likely that the
signiﬁcant decrease in Cmax was brought about mainly by
ad e c r e a s ei nF particularly due to decreased availability
in the process of intestinal mucosal passage. Therefore, the
repeated treatment of Saireito would induce the expression
and activity of intestinal CYP3A, and further accelerate
the metabolism of nifedipine and resulted in a decrease
in the bioavailability. In fact, the CYP3A protein appeared
to be induced by subchronic treatment with Saireito or
Hochuekkito (Figure 3), supporting the idea that formulas
are inducer of the intestinal CYP3A isoform in vivo.T h e
inductive mechanism of Saireito on CYP3A protein need to
be further investigated.
On the other hand, a discrepant report in terms of
Saireito (Kanebo Ltd.) on the pharmacokinetic of nifedipine
in vivo has been published by Ikehata et al. [17]. Although
the values of Cmax and AUC for the control groups were
higher than those reported by Ikehata, the values of F
were almost the same. The diﬀerence in pharmacokinetics
of nifedipine might result from the diﬀerences in the
experimental method,sincein ourstudyratwas anesthetized
and nifedipine was intrajejunum administrated. However,
in the report by Ikehata, rat was not anesthetized and
nifedipine was orally administrated. Moreover, there was no
apparent diﬀerence between the in vivo pharmacokinetics
of nifedipine in our study and those in another report
by Mohri et al. [18]. Herbal agents are complex mixtures
of various phytochemicals, whose absorption and distribu-
tion must vary. That may be one of the reasons for the
inconsistent results between in vivo and in vitro studies.
Furthermore, this apparent contradiction may arise due to
ad i ﬀerence of botanical origin revealed by the scientiﬁc
taxonomic nomenclature (Japanese Pharmacopeia, 2007),
namely Atractylodes Lancea Rhizome: Sojutsu (originated
in A. lancea DE CANDOLLE or A. chinensis KOIDZUMI)
versus A. Rhizoma: Byakujutsu (originated in A. japonica
KOISZUMI ex KITAMURA or A. ovata DE CANDOLLE).
The ingredient ratios between both Saireito (by Tsumura
Ltd and Kanebo Ltd) are also diﬀerent. Although both
Sojutsu and Byakujutsu are collected in compliance with
the Japanese Pharmacopeia, the Saireito recipe depends
on each pharmaceutical company. The standards in this
Pharmacopeia do not reﬂect the traditional knowledge on
eﬃcacy or safety of the botanical resources. It is important
to build modern quality assurance standards for kampo
medicines that were based on the standards built up over
centuries within traditional health cultures themselves.
We should adopt proper strategies tominimize the
negative interactions. It is also notable that the inductive
aﬀect by Saireito orally in advance for 7 day was gone. Thus,
these models may be used in combination warning and
proper advice to patients in clinical practice [19, 20].
Previous in vitro studies revealed that schisandra fruit,
ephedra herb and cinnamon bark had strong inhibitory
eﬀect on microsomal CYP3A activity in rat and human [21,
22]. Makino et al. [23] evaluated the inhibitory eﬀects of the
kampo formula (Shoseiryuto) contained above ingredients
on rat CYP3A in vitro and in vivo. Although Shoseiryuto
inhibited rat CYP3A activity in vitro, it did not signiﬁcantly
aﬀect a plasma concentration proﬁle of nifedipine in rats.Evidence-Based Complementary and Alternative Medicine 9
Interestingly, clinical studies have also revealed that Sho-
seiryuto causes no eﬀect on CYP3A4 [24].
Limited literature in negative drug-herb interactions
generated inconsistencies and controversies regarding the
exact action of these herbs. In vivo and in vitro screening
models will play a major role in identifying possible herb-
drug interactions and thus create a platform for clinical
studies to emerge [6]. In this study, experimental animals
were used for several purposes: (i) to elucidate the aﬀects of
repeated orally administrated kampo medicines on CYP3A;
(ii) to study the eﬀects of kampo medicine on the kinetics
of nifedipine administrated by diﬀerent ways; (iii) to study
the aﬀects of kampo medicine using liver and small intestine
microsome; and (iv) to study the reversibility of eﬀects
caused by kampo medicine.
5.Conclusions
We have demonstrated that subchronic ingestion of Saireito
or Hochuekkito may alter the pharmacokinetics of nifedip-
ine. However, since there is marked overlap in the substrates
of CYP3A4 and P-gp, the aﬀects of kampo medicines on
P-gp should also be investigated in vivo to predict changes
in the pharmacokinetics of CYP3A substrates. In addition,
the eﬀects of more relevant dose used in the present study is
approximately 10 times greater than the standard daily dose
ingested by humans. Further studies are required before any
ﬁnal conclusion between prescribed medicines and Saireito
and Hochuekkito.
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